Botox King Allergan Plumps up Beauty Biz with $2.5 Billion Zeltiq Fat Buster Buy

SUGAR LAND--February 15, 2017--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Allergan plc (NYSE:AGN) (Dublin, Ireland) continues its buying spree with the $2.5 billion bid for Zeltiq Aesthetics (NASDAQ: ZLTQ) (Pleasanton, California). Why Zeltiq? The company complements Allergan's medical aesthetic portfolio, as its lead product is the CoolSculpting System, an FDA-cleared system that reduces unwanted fat. Using patented cooling technology, it is a non-invasive alternative to liposuction.